ClinicalTrials.gg
CompletedNCT04578028Updated Dec 30, 2021

A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of ONO-2808-01 in Healthy Participants

A Phase 1 interventional study of ONO-2808 and Placebo in Neurodegenerative Diseases, sponsored by Ono Pharmaceutical Co. Ltd. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-30.

Sponsored by Ono Pharmaceutical Co. Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Neurodegenerative Diseases with a site in United Kingdom — 11 open to participants now, 19 under way, 4 of them phase 3. Neurodegenerative Diseases · United Kingdom.

Enrollment
21st of 40
94 · median 119
Started
2020
with 2 others
Phase 1
7 of 50
2 open now
Registered
21st of 50
by date

Among the 50 studies in Neurodegenerative Diseases with a site in United Kingdom, this one is the 21st largest by enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2020, is one of 7 in phase 1, and was the 21st registered.

Neurodegenerative Diseases

436 studies on the registry are indexed under Neurodegenerative Diseases; 143 are open to participants now.

Browse Neurodegenerative Diseases studies →

Open to participants now

11 of the 50 studies in Neurodegenerative Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 101 Neurodegenerative Diseases studies recruiting now, 52 (51%) set no upper age limit and 11 (11%) stop at 75 or younger; 20 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Neurodegenerative Diseases with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a first in human study to determine the safety, tolerability and pharmacokinetics of ONO-2808 in healthy adult participants. The study will be conducted in 3 parts: Part A, a single-ascending dose part with an assessment of the potential food effects in non-Japanese adult participants; Part B, a single dose part to assess the effect of age in non-Japanese elderly participants; and Part C, a multiple-ascending dose part with ONO-2808 administered to healthy subjects.

03

Conditions studied

  • Neurodegenerative Diseases

Keywords

  • Neurodegenerative Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide fully informed written consent.
  2. 18-55 years (Part A \& C) or ≥65 years (Part B).
  3. Male and female participants (Women of non-child bearing potential (WONCBP)).
  4. Agree to use an effective method of .
  5. No medical history and no abnormal physical examination, laboratory profiles, vital signs or abnormalities, based on the Screening examination.
  6. (BMI) of ≥18.5 to \<30 kg/m2 and a body weight of at least 50 kg for males and 45 kg for females to a maximum of 100 kg, at the time of screening.
  7. Estimated (CrCL, Cockcroft-Gault equation) ≥90 mL/min at Screening. In Part B only, an estimated CrCL of ≥60mL/min at Screening.

Exclusion criteria

Exclusion Criteria:

  1. Mentally or legally incapacitated or with significant emotional problems at the time of the Screening visit or expected during the conduct of the study.
  2. History or presence of medical, surgical or psychiatric condition (including history of suicidal behaviour) or objection by General Practitioner (GP) to participant entering trial.
  3. Liver chemistry values above the (ULN) at Screening or admission.
  4. Sensitivity to the study drug.
  5. Female who is pregnant or lactating or of .
  6. History or presence of alcoholism or drug/chemical/substance abuse.
  7. Evidence of poor venous access as assessed by PI.
  8. Use of any medication which may affect ONO-2808 pharmacokinetics or pharmacodynamics
  9. Current smoker or has smoked (including use of tobacco and/or nicotine-containing products) in the previous 3 months
  10. Positive urine drugs of abuse, cotinine or alcohol results at Screening or admission.
  11. Positive results for (HIV), surface antigen (HBsAg) or virus (HCV).
  12. Supine resting blood pressure less than 90/40 millimeter of mercury (mmHg) or greater than 140/90 mmHg (Part A\& C) and less than 90/40 mmHg or greater than 160/90 mmHg (Part B).
  13. Supine resting pulse rate lower than 40 beats per minute (bpm) or higher than 100 bpm.
  14. Clinically significant history or presence of findings at screening.
  15. Use of any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements within 14 days or five half-lives (whichever is longer) of first dosing and throughout the study.
  16. Consumption or intake of compounds, food or fluids that are known to be a substrate, inducer or inhibitor of CYP450 for 28 days prior to the first dosing and throughout the study.
  17. Donation of blood or significant blood loss within 56 days prior to the first dosing, or plasma donation within 7 days prior to the first dosing.
  18. Participation in another clinical study within the last 3 months (or 5 half-lives of the study drug, whichever is longer) prior to the first dosing.
  19. Objection by PI
  20. Participants who are not willing to eat a high fat breakfast

    Exclusion criteria, applicable to all participants undergoing lumbar puncture for CSF collection (Part A \& C):

  21. History of significant back pain, significant kyphosis and or scoliosis or other spinal column deformities.
  22. History or evidence of fundoscopy suggestive of raised intracranial pressure.
  23. History or presence of any allergy or to the local anaesthetic required for participants undergoing lumbar puncture.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    ONO-2808 Part A - Fasted

    Single ascending doses of ONO-2808 or placebo orally under fasted conditions. Additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial.

    Drug: ONO-2808

  • Placebo comparator
    ONO-2808 Placebo Part A- Fasted

    Single ascending doses of ONO-2808 or placebo orally under fasted conditions

    Drug: Placebo

  • Experimental
    ONO-2808 Part A - Fed

    Single ascending doses of ONO-2808 or placebo orally under fed conditions

    Drug: ONO-2808

  • Placebo comparator
    ONO-2808 Placebo Part A - Fed

    Single ascending doses of ONO-2808 or placebo orally under fed conditions

    Drug: Placebo

  • Experimental
    ONO-2808 Part B

    Single dose of ONO-2808 or placebo in elderly female or elderly male healthy volunteers .

    Drug: ONO-2808

  • Placebo comparator
    ONO-2808 Placebo Part B

    Single dose of ONO-2808 or placebo in elderly female or elderly male healthy volunteers

    Drug: Placebo

  • Experimental
    ONO-2808 Part C

    Multiple ascending doses of ONO-2808 or placebo orally

    Drug: ONO-2808

  • Placebo comparator
    ONO-2808 Placebo Part C

    Multiple ascending doses of ONO-2808 or placebo orally

    Drug: Placebo

Interventions

  • Investigational drug

  • DrugPlacebo

    Placebo drug

06

What researchers measure

Primary outcomes

  1. Treatment emergent adverse events (TEAEs) by severity.

    Number of participants with TEAEs. An adverse event is any untoward medical occurrence in a participant who receive study drug without regard to possible causal relationship.

    Time frame: Part A and B: up to day 7; Part C: up to 17 days.

  2. Serious adverse events (SAEs)

    Number of participants with SAEs. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged hospitalization, life-threatening experience or persistent disability.

    Time frame: Part A and B: up to day 7; Part C: up to 17 days.

  3. Vital signs

    Summary statistics of vital signs and number of participants with clinically significant changes in vital signs including pulse/heart rate, respiratory rate, and blood pressure

    Time frame: Part A and B: up to day 7; Part C: up to 17 days

  4. ECG parameters

    Number of participants with ECG abnormalities

    Time frame: Part A and B: up to day 7; Part C: up to 17 days.

  5. Clinical laboratory tests

    Number of participants with clinical laboratory abnormalities (including haematology, clinical chemistry and urinalysis)

    Time frame: Part A and B: up to day 7; Part C: up to 17 days

  6. Physical examination

    Number of participants with physical examination abnormalities

    Time frame: Part A and B: up to day 7; Part C: up to 17 days

  7. Neurological examination

    Number of participants with neurological examination abnormalities

    Time frame: Part A and B: up to day 7; Part C: up to 17 days.

  8. Number of participants with suicidal behaviour

    Treatment-emergent suicidal ideation and behaviour will be monitored by using the Columbia Suicide Severity Rating Scale (C-SSRS) and reported.

    Time frame: Part C: up to 17 days

Secondary outcomes

  1. Pharmacokinetics (Cmax)

    Assessment of the maximum observed plasma concentration of ONO-2808

    Time frame: Part A & B: Day 1 through Day 7, Part C: Day 1 and 14

  2. Pharmacokinetics (Tmax)

    Assessment of the time to reach Tmax for ONO-2808

    Time frame: Part A & B: Day 1 through Day 7, Part C: Day 1 and 14

  3. Pharmacokinetics (AUClast)

    Assessment of the area under the concentration-time curve of ONO-2808 to last measurable concentration

    Time frame: Part A & B: Day 1 through Day 7

  4. Pharmacokinetics (AUCinf)

    Assessment of the area under the concentration-time curve of ONO-2808 extrapolated to infinite time in plasma

    Time frame: Part A & B: Day 1 through Day 7

  5. Pharmacokinetics (AUCtau)

    Assessment of the area under the concentration-time curve of ONO-2808 during the dosing interval in plasma

    Time frame: Part C: Day 1 and Day 14

  6. Pharmacokinetics (T1/2)

    Assessment of the terminal elimination half-time of ONO-2808 in plasma

    Time frame: Part A & B: Day 1 through Day 7

  7. Pharmacokinetics (CL/F)

    Assessment of the apparent clearance of ONO-2808 from plasma

    Time frame: Part A & B: Day 1 through Day 7

  8. Pharmacokinetics (Vz/F)

    Assessment of the apparent volume of distribution of ONO-2808 during terminal elimination phase

    Time frame: Part A & B: Day 1 through Day 7

  9. Pharmacokinetics (Aetz)

    Assessment of the amount of ONO-2808 excreted in urine over the period of sample collection

    Time frame: Part A & B: Day 1 through Day 5, Part C: Day 1, 8 & 14

  10. Pharmacokinetics (Percentage fe)

    Assessment of the cumulative percentage of orally administered ONO-2808 excreted into urine

    Time frame: Part A & B: Day 1 through Day 5, Part C: Day 1, 8 & 14

  11. Pharmacokinetics (CLR)

    Assessment of the renal clearance of ONO-2808 from plasma

    Time frame: Part A & B: Day 1 through Day 5, Part C: Day 1, 8 & 14.

  12. Distribution of ONO-2808 to the brain in Part A

    Assessment of ONO-2808 brain distribution by measuring drug concentration in the cerebro spinal fluid (CSF)

    Time frame: Part A (in selected fasted cohorts): Day 1 and 2, Part C: Day 1 and Day 14

07

Study locations

1 site
  • Parexel International Early Phase Clinical Unit (EPCU)
    London, HA1 3UJ, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Aug 2021, 12 months.

Of 29 phase 1 interventional studies under Neurodegenerative Diseases, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2020
First posted
Oct 8, 2020
StartActual
Aug 19, 2020
Primary completionActual
Aug 26, 2021
CompletionActual
Oct 7, 2021
Last update
Dec 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04578028
Collaborators
Parexel
Responsible party
Sponsor
First posted
Oct 8, 2020
Start date
Aug 19, 2020
Primary completion
Aug 26, 2021
Completion
Oct 7, 2021
Last update
Dec 30, 2021

Study contacts

Pablo F Soto, MD,MSc, PhD
principal investigator · Parexel

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ONO-2808

Start the discussion